Looksmaxxing in 2026 means progressive intervention: start with topical retinoids and craniofacial remodeling through orthodontics, escalate to oral minoxidil at 2.5–5 mg daily and peptide-driven collagen synthesis, then move to surgical modification of bone structure when non-invasive methods plateau. This looksmaxxing roadmap separates softmaxxing—interventions reversible or minimally invasive—from hardmaxxing, the permanent structural changes via osteotomy, implants, or tissue grafting. The dividing line is permanence and invasiveness, not efficacy. A 12-week course of MK-677 at 25 mg daily will increase IGF-1 by 60–90% and modestly improve skin turgor; a sliding genioplasty moves your mental protuberance 8 mm forward forever.
Mechanism
Softmaxxing exploits receptor-mediated signaling and extracellular matrix remodeling without altering skeletal geometry. Tretinoin (all-trans retinoic acid) binds retinoic acid receptors (RARα, RARβ, RARγ) in keratinocytes and fibroblasts, upregulating collagen I and III synthesis while inhibiting matrix metalloproteinase-1, the primary collagenase. This reduces photodamage, fine rhytides, and dyspigmentation over 12–24 weeks at 0.025–0.1% topical concentration.
Minoxidil, a potassium channel opener, increases dermal papilla cell proliferation and extends anagen phase duration in hair follicles. Oral administration at 2.5–5 mg daily bypasses the scalp-only limitation of topical formulations and produces diffuse hair density improvement across beard, eyebrows, and scalp within 3–6 months. The sulfotransferase enzyme in hair follicles converts minoxidil to minoxidil sulfate, the active metabolite.
Growth hormone secretagogues—MK-677 (ibutamoren), CJC-1295, ipamorelin—stimulate pituitary GH release via ghrelin receptor agonism or GHRH receptor agonism. Elevated GH drives hepatic IGF-1 production, which binds IGF-1 receptors on fibroblasts, osteoblasts, and chondrocytes. Result: increased collagen deposition, modest bone density improvement, and enhanced wound healing. MK-677 at 25 mg daily increases IGF-1 from baseline ~180 ng/mL to 280–320 ng/mL within 14 days.
Hardmaxxing bypasses biochemical signaling entirely. Rhinoplasty physically reduces or augments nasal cartilage and bone. Sliding genioplasty cuts and repositions the mandibular symphysis. Zygomatic osteotomy or malar implants widen the midface. Buccal fat pad excision removes Bichat’s fat pad to expose masseteric contour. These interventions directly alter craniofacial proportions through mechanical restructuring, not receptor activation.
Protocol
Phase 1: Dermatological Optimization (Weeks 1–24)
Begin tretinoin 0.025% cream nightly for 4 weeks, then escalate to 0.05% if tolerated. Apply to clean, dry skin 20 minutes after washing. Expect erythema and desquamation in weeks 2–4; this is retinoic acid receptor-mediated epidermal turnover, not damage. Pair with broad-spectrum SPF 50+ sunscreen containing zinc oxide or titanium dioxide every morning; tretinoin increases photosensitivity by thinning stratum corneum. By week 12, observe reduced pore diameter, improved skin texture, and fading of post-inflammatory hyperpigmentation.
Add oral minoxidil 2.5 mg daily with breakfast. Monitor for peripheral edema and reflex tachycardia in the first 2 weeks; if systolic BP drops >10 mmHg or resting HR exceeds 85 bpm, reduce to 1.25 mg daily. Increase to 5 mg daily at week 8 if no adverse effects. Hair shedding (telogen effluvium) occurs at weeks 4–8 as minoxidil synchronizes follicles into anagen; this precedes regrowth at weeks 12–16. Expect visible eyebrow and beard density gains by week 20.
Phase 2: Growth Factor Amplification (Weeks 12–36)
Introduce MK-677 25 mg nightly, 60 minutes before bed to exploit endogenous GH pulse timing. Baseline fasting glucose and HbA1c before starting; MK-677 increases insulin resistance transiently. Target IGF-1 level: 280–350 ng/mL at week 4 bloodwork. If IGF-1 exceeds 400 ng/mL, reduce to 12.5 mg daily. Run for 12–16 weeks, then cycle off for 8 weeks to restore endogenous GH pulsatility.
Alternative: CJC-1295 no-DAC 100 mcg subcutaneously 3x weekly plus ipamorelin 200 mcg per injection. This provides pulsatile GH elevation without the continuous receptor occupancy of MK-677, reducing insulin resistance risk. Inject in the evening, at least 3 hours after last meal. Cycle 12 weeks on, 4 weeks off.
Phase 3: Structural Modification (Months 9+)
Once soft tissue optimization plateaus—tretinoin has maximized collagen remodeling, minoxidil has filled density gaps, GH secretagogues have improved skin quality—evaluate hardmaxxing candidacy. Key decision: does your phenotype limitation come from bone structure, soft tissue distribution, or both? Photograph yourself in standardized lighting at 0°, 45°, and 90° angles. Measure facial thirds, nasofrontal angle, mentocervical angle.
Rhinoplasty addresses dorsal hump, nasal tip projection, alar base width. Consult a surgeon with craniofacial fellowship training. Request DICOM imaging and 3D simulation. Recovery: 7 days heavy edema, 6 weeks to resume lifting, 12 months for final contour.
Sliding genioplasty or mandibular angle implants correct weak chin projection or narrow lower third. Genioplasty advances the mental protuberance 6–10 mm; combined with bimax surgery, this corrects Class II malocclusion and recession simultaneously. Angle implants widen gonial angle from 110° to 120°, creating a more squared jawline.
Buccal fat removal eliminates midface fullness in individuals with prominent Bichat’s fat pads. Intraoral incision, 45-minute procedure, 10 days swelling. Results visible at 6 weeks, final at 6 months. Contraindicated if BMI <18 or age >35, as natural fat atrophy will create hollowing.
Monitoring
Baseline labs before starting any protocol: CBC, CMP, lipid panel, fasting glucose, HbA1c, TSH, free T3, IGF-1, testosterone (total and free), estradiol, prolactin. Repeat at 4-week intervals during active intervention.
Tretinoin: Clinical assessment only. Watch for persistent erythema beyond week 6, which suggests barrier disruption. Reduce frequency to every other night if transepidermal water loss causes tightness or stinging.
Oral Minoxidil: Systolic and diastolic BP weekly for first month. Resting heart rate daily. Ankle circumference if edema develops—>5% increase from baseline warrants dose reduction. Potassium level at week 4 (minoxidil can cause mild hyperkalemia via renal potassium channel effects).
MK-677: Fasting glucose and HbA1c at week 4, then every 8 weeks. IGF-1 at weeks 2, 8, and 16. Target IGF-1: 280–350 ng/mL. Fasting glucose >105 mg/dL or HbA1c >5.7% indicates insulin resistance; add 500 mg metformin ER daily or switch to pulsatile peptide protocol. Prolactin can rise 20–40% due to ghrelin receptor cross-reactivity; if >25 ng/mL with gynecomastia symptoms, discontinue and switch to CJC/ipamorelin.
Post-Surgical: Follow surgeon’s wound care protocol. Monitor for signs of infection (erythema spreading >2 cm from incision, fever >100.5°F, purulent discharge). Numbness at mental nerve distribution post-genioplasty resolves in 80% by 6 months; persistent paresthesia beyond 12 months suggests nerve transection and may require revision.
Risks and Mitigation
Tretinoin: Photosensitivity and barrier disruption. Mitigate with SPF 50+ zinc oxide sunscreen reapplied every 2 hours of sun exposure. If irritation occurs, reduce to 3x weekly application and buffer with niacinamide serum applied 10 minutes before tretinoin.
Oral Minoxidil: Hypertrichosis (unwanted hair growth), peripheral edema, reflex tachycardia. Hypertrichosis affects 30% of users at 5 mg daily; not dangerous but cosmetically undesirable. Edema resolves with 25 mg hydrochlorothiazide daily. Tachycardia >90 bpm resting warrants dose reduction or addition of 12.5 mg metoprolol daily.
MK-677: Insulin resistance, water retention, increased appetite, elevated prolactin. Insulin resistance: add 500–1000 mg metformin ER or 200 mcg chromium picolinate daily. Water retention: reduce sodium intake to <2000 mg daily; if persistent, add 25 mg HCTZ. Appetite increase (+300–500 kcal/day): track intake, increase protein to 1.2 g/lb to improve satiety. Prolactin-driven gynecomastia: 0.25 mg cabergoline twice weekly.
Surgical Hardmaxxing: Infection, nerve damage, implant malposition, asymmetry. Infection rate <2% with prophylactic antibiotics (cephalexin 500 mg QID for 7 days post-op). Nerve damage in genioplasty affects inferior alveolar or mental nerve in 10–15%; >80% resolve spontaneously. Implant malposition requires revision surgery; choose a surgeon with >100 cases in the specific procedure.
Comparisons
MK-677 vs. CJC-1295/Ipamorelin: MK-677 provides continuous ghrelin receptor agonism, raising GH and IGF-1 for 24 hours per dose. Simpler (oral), cheaper ($60/month), but higher insulin resistance risk. CJC/ipamorelin delivers pulsatile GH elevation mimicking natural secretion, reducing metabolic disruption. More expensive ($180/month), requires injection skill, but better for individuals with prediabetes or family history of type 2 diabetes. Both raise IGF-1 60–90% from baseline at standard doses.
Genioplasty vs. Chin Implant: Sliding genioplasty cuts and advances the mandibular symphysis, preserving mental nerve and offering vertical or horizontal adjustment. Permanent, no foreign material, superior aesthetic outcome. Requires general anesthesia, 6-week recovery, $8,000–$12,000. Chin implant is faster (local anesthesia, 45 minutes, $4,000–$6,000), but implants can shift, erode underlying bone, or become palpable. Genioplasty is the gold standard for significant advancement >6 mm.
Rhinoplasty vs. Non-Surgical Nose Job: Non-surgical rhinoplasty uses hyaluronic acid filler to camouflage dorsal hump or augment tip projection. Temporary (12–18 months), $800–$1,500, no downtime. Cannot reduce size, only augment. Carries risk of vascular occlusion if filler enters dorsal nasal artery—blindness or nasal necrosis. Surgical rhinoplasty provides definitive reshaping, reduction, and structural correction. One-time cost $8,000–$15,000, permanent results.
Common Mistakes
1. Starting Tretinoin at 0.1% Concentration: Retinoic acid receptor activation causes keratinocyte turnover; jumping to high concentration without acclimation produces severe desquamation and non-compliance. Start low, titrate over 8–12 weeks.
2. Running MK-677 Continuously for 6+ Months: Prolonged ghrelin receptor agonism desensitizes pituitary somatotrophs and worsens insulin resistance. Cycle 12–16 weeks on, 8 weeks off to preserve endogenous pulsatility.
3. Using Oral Minoxidil Without Blood Pressure Monitoring: Minoxidil is a peripheral vasodilator developed as an antihypertensive. Reflex tachycardia and hypotension are dose-dependent. Check BP weekly for the first month, adjust dose if systolic drops >10 mmHg.
4. Pursuing Hardmaxxing Before Optimizing Body Composition: Facial aesthetics are body-fat-percentage-dependent. Buccal fat removal or jaw implants look dramatically different at 12% vs. 20% body fat. Reach 10–12% body fat, hold for 8 weeks, reassess structure under optimal conditions.
5. Choosing Surgeon Based on Price: Craniofacial surgery has high skill variance. A poorly positioned jaw implant or overly aggressive rhinoplasty requires revision surgery at 2x the cost and risk. Vet surgeons on case volume (>100 in specific procedure), fellowship training (craniofacial or facial plastics), and 3D imaging capability.
Bottom Line
- Softmaxxing first: Tretinoin 0.05% nightly, oral minoxidil 2.5–5 mg daily, MK-677 25 mg nightly in 12-week cycles. Expect 12–24 weeks for visible collagen and hair density changes.
- Monitor metabolic markers: Fasting glucose, HbA1c, IGF-1 every 4–8 weeks on GH secretagogues. Add metformin 500 mg ER if glucose >105 mg/dL.
- Hardmaxxing after plateau: Rhinoplasty, genioplasty, or zygomatic implants once soft tissue optimization is maximized and body fat ≤12%.
- Surgical quality over cost: Choose fellowship-trained surgeons with >100 cases in the specific procedure and 3D imaging capability.
- Progressive intervention: This looksmaxxing roadmap moves from reversible to permanent. Lock in gains at each phase before escalating.